Acurx Pharmaceuticals LLC, a clinical stage, privately-held biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, announced yesterday that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for ACX-362E, an investigational new treatment for Clostridium difficile Infection (CDI).
The product is a novel, oral antibiotic that recently entered Phase one development. It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.
David P Luci, co-founder & managing partner of Acurx, said, 'FDA's granting of Fast Track designation for our lead antibiotic program validates our business model, which includes a pipeline of DNA polymerase IIIC Inhibitors we are currently developing to treat other resistant bacterial infections.'
Acurx intends to complete the drug's Phase 1 clinical trial in the second quarter of 2019 and is planning to advance ACX-362E into a Phase 2 clinical trial in the fourth quarter of 2019.
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Astellas Pharma's CRESEMBA receives orphan drug and paediatric exclusivity from FDA
SK Biopharmaceuticals' cenobamate achieves 100,000 patient treatment milestone
Calliditas Therapeutics' Nefecon receives additional seven years orphan drug exclusivity from US FDA
Merck finalises acquisition of Harpoon Therapeutics Inc
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Celltrion USA submits CT-P39 Biologics License Application to FDA
iOnctura's first-in-class autotaxin cancer therapy granted US FDA Orphan Drug Designation
Epitomee submits Weight Loss Capsule for FDA approval in US
Calliditas Therapeutics TARPEYO receives seven years orphan drug exclusivity from US FDA
Camurus reports Oclaiz NDA accepted by FDA for acromegaly treatment
TME Pharma plans NOX-A12 Phase 2 trial in brain cancer after FDA IND clearance